vimarsana.com

Page 42 - கதிர்வீச்சு புற்றுநோயியல் நிபுணர் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Dana-Farber Cancer Institute faculty recognized as 2021 ASCO leaders in cancer care

Date Time Dana-Farber Cancer Institute faculty recognized as 2021 ASCO leaders in cancer care The American Society of Clinical Oncology (ASCO) recognized two Dana-Farber Cancer Institute researchers as winners of ASCO’s Special Awards, the Society’s highest honors. The recipients of these awards have worked to transform cancer care around the world. Among the recipients: Jennifer A. Ligibel, MD is the Director of the Leonard P. Zakim Center for Integrative Therapies and Healthy Living and the Director of the Center for Faculty Well-Being at Dana-Farber Cancer Institute, as well as an Associate Professor of Medicine at Harvard Medical School. Dr. Ligibel has dedicated her career to studying the role of exercise and weight management in the prevention and treatment of breast cancer and is a senior physician at the Susan F. Smith Center for Women’s Cancer at Dana-Farber. The Hologic, Inc Endowed Women Who Conquer Cancer Mentorship Award honors Dr. Ligibel as an extraordinary f

Experts: Cancer Deaths May Reduce if Patients Seek Medical Help Early

By Chiamaka Ozulumba Cancer specialists and oncologists have said that Nigeria’s estimated 72,000 annual cancer burden and deaths may reduce if patients seek appropriate medical help early. This and others were the areas of discussion at the virtual 7th Oncology Webinar series put together by Lakeshore Cancer Center, Victoria Island recently on the theme, “Palliative and Supportive Care in Oncology Management”. The speakers for this webinar were: Senior Resident in Radiation Oncology at the NLCC (NSIA-LUTH Cancer Center), Dr. Chidi Agbakwuru; Consultant Medical Oncologist, University Hospitals of Leicester NHS Trust, Dr. Chinenye Iwuji; Clinical Psychologist, Busola Olamuyiwa; lthe Medical Director of PainDoc Africa Limited,

PreludeDx PREDICT Study Demonstrates High Clinical Utility of DCISionRT for DCIS Breast Cancer Patients

PreludeDx PREDICT Study Demonstrates High Clinical Utility of DCISionRT for DCIS Breast Cancer Patients 42% change in treatment recommendations when using DCISionRT News provided by Share this article Share this article LAGUNA HILLS, Calif., April 21, 2021 /PRNewswire/  Prelude Corporation (PreludeDx™), a leader in molecular diagnostics and precision medicine for early stage breast cancer, announced results for a  prospective study in 44 U.S. academic and community cancer centers that evaluated the impact of DCISionRT on clinicians recommendations to administer or omit adjuvant radiotherapy (RT) in patients with DCIS (ductal carcinoma in situ) following breast conserving surgery (BCS). Data published today in the

PreludeDx PREDICT Study Demonstrates High Clinical Utility of DCISionRT for DCIS Breast Cancer Patients

PreludeDx PREDICT Study Demonstrates High Clinical Utility of DCISionRT for DCIS Breast Cancer Patients
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

ZAP Surgical Systems, Inc : ZAP Surgical Announces Future Installation of Novel Non-Invasive Brain Tumor Treatment System in Munich, Germany

ZAP Surgical Systems, Inc : ZAP Surgical Announces Future Installation of Novel Non-Invasive Brain Tumor Treatment System in Munich, Germany
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.